These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 37915617)
21. Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer). Abou-Alfa GK; Lau G; Kudo M; Chan SL; Kelley RK; Furuse J; Sukeepaisarnjaroen W; Kang YK; Dao TV; De Toni EN; Rimassa L; Breder V; Vasilyev A; Heurgué A; Tam VC; Mody K; Thungappa SC; Ostapenko Y; Yau T; Azevedo S; Varela M; Cheng AL; Qin S; Galle PR; Ali S; Gupta C; Makowsky M; Kurland JF; Negro A; Sangro B Future Oncol; 2023 Dec; 19(38):2505-2516. PubMed ID: 37671641 [TBL] [Abstract][Full Text] [Related]
22. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. Feng MY; Chan LL; Chan SL Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172 [TBL] [Abstract][Full Text] [Related]
23. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. Duffy AG; Ulahannan SV; Makorova-Rusher O; Rahma O; Wedemeyer H; Pratt D; Davis JL; Hughes MS; Heller T; ElGindi M; Uppala A; Korangy F; Kleiner DE; Figg WD; Venzon D; Steinberg SM; Venkatesan AM; Krishnasamy V; Abi-Jaoudeh N; Levy E; Wood BJ; Greten TF J Hepatol; 2017 Mar; 66(3):545-551. PubMed ID: 27816492 [TBL] [Abstract][Full Text] [Related]
24. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence. Cerreto M; Cardone F; Cerrito L; Stella L; Santopaolo F; Pallozzi M; Gasbarrini A; Ponziani FR Curr Oncol; 2023 Sep; 30(10):8774-8792. PubMed ID: 37887533 [TBL] [Abstract][Full Text] [Related]
25. FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma. Patel TH; Brewer JR; Fan J; Cheng J; Shen YL; Xiang Y; Zhao H; Lemery SJ; Pazdur R; Kluetz PG; Fashoyin-Aje LA Clin Cancer Res; 2024 Jan; 30(2):269-273. PubMed ID: 37676259 [TBL] [Abstract][Full Text] [Related]
26. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. Plaz Torres MC; Lai Q; Piscaglia F; Caturelli E; Cabibbo G; Biasini E; Pelizzaro F; Marra F; Trevisani F; Giannini EG J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34361985 [TBL] [Abstract][Full Text] [Related]
27. Safety and Long-Term Survival Outcome in Patients With Unresectable Barcelona Clinic Liver Cancer (BCLC) Stages C and D Advanced Hepatocellular Carcinoma Treated With 40 μm Drug-Eluting Bead Transcatheter Arterial Chemoembolization. Wholey M; Palacios Iii R; Wholey D; Mendez A Cureus; 2022 Apr; 14(4):e24047. PubMed ID: 35573558 [TBL] [Abstract][Full Text] [Related]
29. Recent developments with immunotherapy for hepatocellular carcinoma. Waidmann O Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439 [TBL] [Abstract][Full Text] [Related]
30. Management of hepatocellular in the United States. Mokdad AA; Hester CA; Singal AG; Yopp AC Chin Clin Oncol; 2017 Apr; 6(2):21. PubMed ID: 28482674 [TBL] [Abstract][Full Text] [Related]
34. Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma. Song X; Kelley RK; Green M; Standifer N; Lim K; Zhou D; Dunyak J; Negro A; Kurland JF; Ren S; Khan AA; Gibbs M; Abou-Alfa GK Clin Pharmacol Ther; 2023 Oct; 114(4):874-882. PubMed ID: 37422678 [TBL] [Abstract][Full Text] [Related]
35. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Wang EA; Stein JP; Bellavia RJ; Broadwell SR Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319 [TBL] [Abstract][Full Text] [Related]
36. Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Choi C; Choi GH; Kim TH; Tanaka M; Meng MB; Seong J Liver Cancer; 2014 Oct; 3(3-4):405-16. PubMed ID: 26280002 [TBL] [Abstract][Full Text] [Related]
37. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Chen Y; Hu H; Yuan X; Fan X; Zhang C Front Immunol; 2022; 13():896752. PubMed ID: 35757756 [TBL] [Abstract][Full Text] [Related]
38. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. Marzi L; Mega A; Gitto S; Pelizzaro F; Seeber A; Spizzo G Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884392 [TBL] [Abstract][Full Text] [Related]
39. Current systemic treatment of hepatocellular carcinoma: A review of the literature. Chen KW; Ou TM; Hsu CW; Horng CT; Lee CC; Tsai YY; Tsai CC; Liou YS; Yang CC; Hsueh CW; Kuo WH World J Hepatol; 2015 Jun; 7(10):1412-20. PubMed ID: 26052386 [TBL] [Abstract][Full Text] [Related]
40. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. Abou-Alfa GK; Lau G; Kudo M; Chan SL; Kelley RK; Furuse J; Sukeepaisarnjaroen W; Kang YK; Van Dao T; De Toni EN; Rimassa L; Breder V; Vasilyev A; Heurgué A; Tam VC; Mody K; Thungappa SC; Ostapenko Y; Yau T; Azevedo S; Varela M; Cheng AL; Qin S; Galle PR; Ali S; Marcovitz M; Makowsky M; He P; Kurland JF; Negro A; Sangro B NEJM Evid; 2022 Aug; 1(8):EVIDoa2100070. PubMed ID: 38319892 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]